NASDAQ:OHRP

OHR Pharmaceutical (OHRP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.42
$0.45
50-Day Range
$5.39
$9.07
52-Week Range
$1.60
$6.28
Volume
21,218 shs
Average Volume
180,228 shs
Market Capitalization
$1.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OHRP stock logo

About OHR Pharmaceutical Stock (NASDAQ:OHRP)

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

OHRP Stock News Headlines

Pharmaceutical Stocks
CYCC Cyclacel Pharmaceuticals, Inc.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
OHR Pharmaceutical (OHRP) is now in Oversold Territory
See More Headlines
Receive OHRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OHR Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2018
Today
4/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OHRP
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-13,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.86 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.19 million
Optionable
Not Optionable
Beta
0.84
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Jason Scott Slakter (Age 61)
    CEO, Pres & Director
  • Mr. Samuel Backenroth (Age 35)
    CFO, VP of Bus. Devel. & Sec.
  • Dr. Glenn L. Stoller M.D. (Age 55)
    Chief Scientific Officer
  • Dr. Marlene Modi
    Head of Preclinical & Regulatory Affairs

OHRP Stock Analysis - Frequently Asked Questions

How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) posted its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter.

When did OHR Pharmaceutical's stock split?

OHR Pharmaceutical shares reverse split before market open on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 1st 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OHR Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), IVERIC bio (OPHT), Novavax (NVAX), Immunomedics (IMMU), OPKO Health (OPK), Dynavax Technologies (DVAX) and Energy Transfer (ET).

This page (NASDAQ:OHRP) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners